nach oben

Erschienen in:

01.04.2012 | Original Article

Differentiation-inducing factor-1 enhances 5-fluorouracil action on oral cancer cells inhibiting E2F1 and thymidylate synthase mRNAs accumulation

verfasst von: Andrea Elio Sprio, Federica Di Scipio, Paolo Ceppi, Paolina Salamone, Francesco Di Carlo, Giorgio Vittorio Scagliotti, Mauro Papotti, Adriano Ceccarelli, Giovanni Nicolao Berta

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 4/2012

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Differentiation-inducing factor-1 (DIF-1) is a morphogen originally identified in the amoebozoan Dictyostelium discoideum. In mammalian cells, it has been shown to activate GSK3β, which in turn is expected to reduce levels of β-catenin and cyclin D1, thus mediating DIF-1 antiproliferative properties. Since this could alter the expression and activity of E2F1 transcription factor and consequently those of the prognostic marker/chemotherapy target thymidylate synthase (TS), we evaluated (1) whether DIF-1 could effectively regulate these genes, (2) whether it could interfere with cell viability, and (3) whether DIF-1 activity could enhance the efficacy of the TS inhibitor 5-fluorouracil (5-FU).

Methods

We investigated the effects of DIF-1 in continuous human cell lines derived from two oral tumor histotypes (corresponding to an adenosquamous and a squamous carcinoma) and a gingival epithelium. We evaluated mRNA accumulation by means of quantitative real-time PCR and efficacy of drugs on cell viability by means of MTT assay.

Results

DIF-1 inhibited the accumulation of E2F1 mRNA and reduces TS mRNA levels in tumor cell lines, but did not alter mRNA levels in the gingival counterpart. As a result, it inhibited proliferation preferentially of tumor cell in time- and concentration-dependent manner. Moreover, it enhanced cytotoxic effects of 5-FU only in tumor cell, whereas reduced them in the gingival counterpart.

Conclusions

These findings suggest a tumor-specific action of DIF-1 on oral carcinoma cells. Thus, interfering with E2F1 and TS transcription, DIF-1 potentiates TS enzymatic inhibitors.

Morris HR, Taylor GW, Masento MS, Jermyn KA, Kay RR (1987) Chemical structure of the morphogen differentiation inducing factor from Dictyostelium discoideum. Nature 328(6133):811–814PubMedCrossRef

Fukuzawa M, Abe T, Williams JG (2003) The Dictyostelium prestalk cell inducer DIF regulates nuclear accumulation of a STAT protein by controlling its rate of export from the nucleus. Development 130(4):797–804PubMedCrossRef

Zhukovskaya NV, Fukuzawa M, Yamada Y, Araki T, Williams JG (2006) The Dictyostelium bZIP transcription factor DimB regulates prestalk-specific gene expression. Development 133(3):439–448PubMedCrossRef

MacWilliams H, Doquang K, Pedrola R, Dollman G, Grassi D, Peis T, Tsang A, Ceccarelli A (2006) A retinoblastoma ortholog controls stalk/spore preference in Dictyostelium. Development 133(7):1287–1297PubMedCrossRef

Kubohara Y (1999) Effects of differentiation-inducing factors of Dictyostelium discoideum on human leukemia K562 cells: DIF-3 is the most potent anti-leukemic agent. Eur J Pharmacol 381(1):57–62PubMedCrossRef

Kanai M, Konda Y, Nakajima T, Izumi Y, Kanda N, Nanakin A, Kubohara Y, Chiba T (2003) Differentiation-inducing factor-1 (DIF-1) inhibits STAT3 activity involved in gastric cancer cell proliferation via MEK-ERK-dependent pathway. Oncogene 22(4):548–554PubMedCrossRef

Mori J, Takahashi-Yanaga F, Miwa Y, Watanabe Y, Hirata M, Morimoto S, Shirasuna K, Sasaguri T (2005) Differentiation-inducing factor-1 induces cyclin D1 degradation through the phosphorylation of Thr286 in squamous cell carcinoma. Exp Cell Res 310(2):426–433PubMedCrossRef

Yasmin T, Takahashi-Yanaga F, Mori J, Miwa Y, Hirata M, Watanabe Y, Morimoto S, Sasaguri T (2005) Differentiation-inducing factor-1 suppresses gene expression of cyclin D1 in tumor cells. Biochem Biophys Res Commun 338(2):903–909PubMedCrossRef

Takahashi-Yanaga F, Taba Y, Miwa Y, Kubohara Y, Watanabe Y, Hirata M, Morimoto S, Sasaguri T (2003) Dictyostelium differentiation-inducing factor-3 activates glycogen synthase kinase-3beta and degrades cyclin D1 in mammalian cells. J Biol Chem 278(11):9663–9670PubMedCrossRef

10.

Du W, Pogoriler J (2006) Retinoblastoma family genes. Oncogene 25(38):5190–5200PubMedCrossRef

11.

Giacinti C, Giordano A (2006) RB and cell cycle progression. Oncogene 25(38):5220–5227PubMedCrossRef

12.

Abramova MV, Zatulovskiy EA, Svetlikova SB, Kukushkin AN, Pospelov VA (2010) e2f1 Gene is a new member of Wnt/beta-catenin/Tcf-regulated genes. Biochem Biophys Res Commun 391(1):142–146PubMedCrossRef

13.

Angus SP, Wheeler LJ, Ranmal SA, Zhang X, Markey MP, Mathews CK, Knudsen ES (2002) Retinoblastoma tumor suppressor targets dNTP metabolism to regulate DNA replication. J Biol Chem 277(46):44376–44384PubMedCrossRef

14.

Duffy MJ (2005) Predictive markers in breast and other cancers: a review. Clin Chem 51(3):494–503PubMedCrossRef

15.

Lehman NL (2002) Future potential of thymidylate synthase inhibitors in cancer therapy. Expert Opin Investig Drugs 11(12):1775–1787PubMedCrossRef

16.

Gioanni J, Fischel JL, Lambert JC, Demard F, Mazeau C, Zanghellini E, Ettore F, Formento P, Chauvel P, Lalanne CM (1988) Two new human tumor cell lines derived from squamous cell carcinomas of the tongue: establishment, characterization and response to cytotoxic treatment. Eur J Cancer Clin Oncol 24(9):1445–1455PubMedCrossRef

17.

Jiang L, Ji N, Zhou Y, Li J, Liu X, Wang Z, Chen Q, Zeng X (2009) CAL 27 is an oral adenosquamous carcinoma cell line. Oral Oncol 45(11):e204–e207. doi:10.1016/j.oraloncology.2009.06.001 PubMedCrossRef

18.

Momose F, Araida T, Negishi A, Ichijo H, Shioda S, Sasaki S (1989) Variant sublines with different metastatic potentials selected in nude mice from human oral squamous cell carcinomas. J Oral Pathol Med 18(7):391–395PubMedCrossRef

19.

Smulow JB, Glickman I (1966) An epithelial-like cell line in continuous culture from normal adult human gingiva. Proc Soc Exp Biol Med 121(4):1294–1296PubMed

20.

Monica V, Scagliotti GV, Ceppi P, Righi L, Cambieri A, Lo Iacono M, Saviozzi S, Volante M, Novello S, Papotti M (2009) Differential thymidylate synthase expression in different variants of large-cell carcinoma of the lung. Clin Cancer Res 15(24):7547–7552PubMedCrossRef

21.

Barker N (2008) The canonical Wnt/beta-catenin signalling pathway. Methods Mol Biol 468(5):5–15PubMedCrossRef

22.

Liu F, Millar SE (2010) Wnt/beta-catenin signaling in oral tissue development and disease. J Dent Res 89(4):318–330PubMedCrossRef

23.

Lenz HJ, Leichman CG, Danenberg KD, Danenberg PV, Groshen S, Cohen H, Laine L, Crookes P, Silberman H, Baranda J, Garcia Y, Li J, Leichman L (1996) Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival. J Clin Oncol 14(1):176–182PubMed

24.

Wada Y, Yoshida K, Suzuki T, Mizuiri H, Konishi K, Ukon K, Tanabe K, Sakata Y, Fukushima M (2006) Synergistic effects of docetaxel and S-1 by modulating the expression of metabolic enzymes of 5-fluorouracil in human gastric cancer cell lines. Int J Cancer 119(4):783–791PubMedCrossRef

25.

Shigematsu H, Yoshida K, Sanada Y, Osada S, Takahashi T, Wada Y, Konishi K, Okada M, Fukushima M (2010) Rapamycin enhances chemotherapy-induced cytotoxicity by inhibiting the expressions of TS and ERK in gastric cancer cells. Int J Cancer 126(11):2716–2725PubMed

26.

Akaishi E, Narita T, Kawai S, Miwa Y, Sasaguri T, Hosaka K, Kubohara Y (2004) Differentiation-inducing factor-1-induced growth arrest of K562 leukemia cells involves the reduction of ERK1/2 activity. Eur J Pharmacol 485(1–3):21–29PubMedCrossRef

27.

Kubohara Y (1997) DIF-1, putative morphogen of D. discoideum, suppresses cell growth and promotes retinoic acid-induced cell differentiation in HL-60. Biochem Biophys Res Commun 236(2):418–422PubMedCrossRef

28.

Miwa Y, Sasaguri T, Kosaka C, Taba Y, Ishida A, Abumiya T, Kubohara Y (2000) Differentiation-inducing factor-1, a morphogen of dictyostelium, induces G(1) arrest and differentiation of vascular smooth muscle cells. Circ Res 86(1):68–75PubMed

Titel: Differentiation-inducing factor-1 enhances 5-fluorouracil action on oral cancer cells inhibiting E2F1 and thymidylate synthase mRNAs accumulation
verfasst von: Andrea Elio Sprio
Federica Di Scipio
Paolo Ceppi
Paolina Salamone
Francesco Di Carlo
Giorgio Vittorio Scagliotti
Mauro Papotti
Adriano Ceccarelli
Giovanni Nicolao Berta
Publikationsdatum: 01.04.2012
Verlag: Springer-Verlag
Erschienen in: Cancer Chemotherapy and Pharmacology / Ausgabe 4/2012
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-011-1790-x

Neu im Fachgebiet Onkologie

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Springer Medizin

Differentiation-inducing factor-1 enhances 5-fluorouracil action on oral cancer cells inhibiting E2F1 and thymidylate synthase mRNAs accumulation